Seeking Alpha

A Delaware court has upheld two patents in favor of Pronova's heart drug Lovaza, ruling against...

A Delaware court has upheld two patents in favor of Pronova's heart drug Lovaza, ruling against Par Pharmaceutical (PRX) and Teva Pharmaceutical (TEVA). The ruling prevents Par and Teva from selling generic versions of Lovaza, which lowers very high levels of triglycerides in the bloodstream.
From other sites
Comments (4)
  • doc47
    , contributor
    Comments (1310) | Send Message
     
    I wonder if all the pro-TEVA bloggers here will try to spin this news along with the Lipitor 'decision" into something that makes TEVA a "buy"!!!
    29 May 2012, 08:37 PM Reply Like
  • chopchop0
    , contributor
    Comments (3936) | Send Message
     
    It's the biggest gainer on my list right now today :)
    30 May 2012, 01:37 PM Reply Like
  • Goeleven
    , contributor
    Comments (629) | Send Message
     
    If I understand well that it is an approval for two medicines than Teva shall certainly go higher.
    30 May 2012, 06:24 AM Reply Like
  • alex haff
    , contributor
    Comments (6) | Send Message
     
    it is a buy
    30 May 2012, 11:01 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs